Admedus adopts cloud-based platform for genital herpes vaccine trial

Admedus Ltd., a specialty health care company that provides innovative medical technologies and devices, recently adopted Medidata's Clinical Cloud platform to help with the development of a therapeutic vaccine for genital herpes.

The Australian-based company hopes to use the platform to improve the speed, efficiency and decision-making process for the vaccine, which is meant to provoke a response from T-cells against the herpes virus.

”It is estimated that up to 20 million people worldwide are newly infected with HSV-2 each year,” Admedus CEO Lee Rodne said. “Our potential therapeutic vaccine could have life-changing effects for these people and future generations. Admedus’ study is currently progressing well and we are expecting some interim results from our Phase II clinical trial later this year.”

The research will benefit herpes patients around the world.

“We’re excited to be working alongside such a forward-thinking organization as Admedus, especially as we expand into the clinical trial landscape in Australia,” Takeru Yamamoto, Medidata’s managing director of the Asia-Pacific region, said. “We share Admedus’ mission of making a difference in the outcomes and quality of life for patients — both in Australia and around the globe — and are proud to power their research as they continue to develop innovative immunotherapies to help treat and prevent infectious diseases.”

Organizations in this Story

Admedus Ltd

Want to get notified whenever we write about Admedus Ltd ?
Next time we write about Admedus Ltd, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.